<i>PLK3</i> amplification and tumor immune microenvironment of metastatic tumors are linked to adjuvant treatment outcomes in uterine serous cancer.

NAR Cancer · 2022 · PMC9513840 · PMID 36177381

Europe PMC DOI

hedged sentences

0.0001

closest p · 0.0× alpha

0.0590

boldest claim

The sentences

highly significantP < 0.0001actually significant

We also observed a highly significant difference ( P < 0.0001) in the proportion of PtR patients (92.5%) compared to PtS patients (7.5%) with TP53 copy loss in the metastatic tumor.

also in 132,142 other papers

approached near significanceP -value = 0.059so close (0.05 < p ≤ 0.1)

Although remarkable differences in the number of breakpoints in primary tumors between PtS and PtR patients (Supplemental Table S4a) were not observed, the mean number of breakpoints for primary tumors in chromosomes 1, 8, 11, 17 (Figure 1A ) was observed to be higher and approached near significance in PtS versus PtR patients (chr1 P -value = 0.059, chr8 P -value = 0.056, chr11 P -value = 0.068, chr17 P -value = 0.058).

also in 11 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.